Compounds

Details Compounds Compounds

2005-11-29

2005-11-29

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S206000, C546S205000, C546S203000

Reexamination Certificate

active

06969724

ABSTRACT:
Compounds of formula I, or a salt thereof or a hydrate thereof, as follows:whereinX and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aryl, heterocyclyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, arylC1-6alkoxy, C1-6alkyl, C1-6alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo;m and n are independently 0 to 3, provided that m and n are not both 0;A represents a single bond or is —(CRpaRpb)p— wherein p is 1-3 and Rpaand Rpbare selected independently from hydrogen, C1-6alkyl, C1-6alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo;B represents a C4-8saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C1-6alkyl, C1-6alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C1-6alkylamino, di(C1-6alkyl)amino, and C1-6alkylamido, which C1-6alkyl or C1-6alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC1-6alkoxy, amino, C1-6alkylamino, di(C1-6alkyl)amino, arylC1-6alkyl, hydroxy, C1-6alkenoxy, C1-6alkoxy, halo, or C1-6alkyl, which C1-6alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

REFERENCES:
patent: 3812119 (1974-05-01), Walker
patent: 4022791 (1977-05-01), Welch, Jr.
patent: 5489599 (1996-02-01), Carter et al.
patent: 28 343 72 (1979-02-01), None
patent: 36 20 358 (1986-12-01), None
patent: 0 825 180 (1998-02-01), None
patent: 2 091 250 (1982-07-01), None
patent: 2 177 085 (1987-01-01), None
patent: WO 98 02432 (1998-01-01), None
patent: WO 98 36749 (1998-08-01), None
patent: WO 00/06545 (2000-02-01), None
Welch, Willard, et al., “Analgesic and Tranquilizing Activity of 5,8-Disubstituted 1-Tetralone Mannich Bases” JOURNAL OF MEDICINAL CHEMISTRY, 1977, vol. 20, No. 5 pp. 699-705, XP-000882092.
Santana, L., et al., “Sintesis de 2-aminometiltetralines como agentes α-bioqueantes y antidopamincergicos”, ANALES DE LA REAL ACADEMIE DE FARMACIA, Vol. 55, Apr. 1989, pp. 461-469, XP-000882145.
Neunier, Jean-Claude, “Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor”,EUROPEAN JOURNAL OF PHARMACOLOGY, NL, ELSEVIER SCIENCE B.V. AMSTERDAM, Vol. 340, Jan. 1997 pp. 1-15, XP 000872550.
Henderson, Graeme & McKnight, Alexander T., The Orphan Opioid receptor and its endogenous ligand-nociceptin/orphanian FQ, TRENDS IN PHARMOACOLOGICAL SCIENCES, G. ELSEVIER SCIENCE LTD., Vol. 18, No. 8, Aug. 1, 1997, pp. 293-300, XP004085920.
Zaki, Paulette A. & Evans, Chris J., “ORL-1: An Awkward Child of the Opioid Receptor Family”, THE NEUROSCIENTIST, Vol. 4, No. 3, Mar. 1998, pp. 172-184, XP 000872580.

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3473591